{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T19:13:04Z","timestamp":1774552384157,"version":"3.50.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Digit. Health"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>This study evaluates the effectiveness of four commercially available automated insulin delivery (AID) systems in routine clinical practice for type 1 diabetes management and compares their first-year outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials<\/jats:title><jats:p>This retrospective study (October 2020\u2013October 2023) included glucometric data from type 1 diabetes patients collected from the Asturias Automatic Insulin Devices Registry. People with type 1 diabetes using four different AID systems [Minimed\u2122780G (MM780G), Accu-Chek\u00ae Insight-Diabeloop (DBLG), Tandem-Control-IQ, and Ypsopump Cambridge HCL-app (Cam-APS)] were included in the study. Primary outcomes were glycaemic control after one year. Secondary outcomes compared the results between the four systems.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>174 patients (60: MM780G, 45: DBLG, 30: Control-IQ, 39: Cam-APS), aged 18\u201373, predominantly women, were enrolled. At baseline, glycemic control, measured by the achievement of the international consensus targets [TBR (Time Below Range) &amp;lt;4%; TIR(Time in Range) &amp;gt;70% and TAR (Time Above Range) &amp;lt;25%] was only met by 9.72% of participants, while after 1 year of an AID system use, it improved to more than 52%. When comparing between systems, TIR improved significantly after 1 year in all systems. However, Control-IQ did not show improvement in mean glucose and Glucose management index (GMI) and only users of DBLG showed improvement in coefficient of variation (CV). MM780G users achieved the best results after 12 months in mean glucose, TIR and GMI. However, their baseline situation was also better than that of the other groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study confirms that, after 12 months of routine clinical use, the use of commercially available automated insulin delivery (AID) systems significantly improves glycemic control in individuals with type 1 diabetes. However, the degree of improvement varies depending on the specific system used.<\/jats:p><jats:p>These findings underscore the importance of selecting and optimizing AID systems individually to maximize clinical benefits in type 1 diabetes management.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fdgth.2025.1596188","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:27:55Z","timestamp":1751347675000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["One-year evaluation of automated insulin delivery systems in adults with type 1 diabetes"],"prefix":"10.3389","volume":"7","author":[{"given":"Pedro","family":"Pujante","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Victoria","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Villa-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Garc\u00eda-Villarino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1s","family":"Gonz\u00e1lez-Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"D\u00edaz-Naya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gala","family":"Guti\u00e9rrez Buey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Veiguela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Rivas-Otero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edelmiro","family":"Men\u00e9ndez-Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u00edas","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Ares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00125-022-05744-z","article-title":"Automated insulin delivery: benefits, challenges, and recommendations. A consensus report of the joint diabetes technology working group of the European Association for the study of diabetes and the American Diabetes Association","volume":"66","author":"Sherr","year":"2023","journal-title":"Diabetologia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s13300-020-00831-z","article-title":"Evolution of insulin delivery devices: from syringes, pens, and pumps to DIY artificial pancreas","volume":"11","author":"Kesavadev","year":"2020","journal-title":"Diabetes Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1089\/dia.2021.0203","article-title":"Real-world performance of the MiniMedTM 780G system: first report of outcomes from 4120 users","volume":"24","author":"Silva","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/19322968231187915","article-title":"Real-world evidence of the Cambridge hybrid closed-loop app with a novel real-time continuous glucose monitoring system","volume":"1","author":"Newman","year":"2023","journal-title":"J Diabetes Sci Technol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1089\/dia.2022.0449","article-title":"Safety, and satisfaction with the accu-chek insight with diabeloop closed-loop system in subjects with type 1 diabetes: a multicenter real-world study","volume":"25","author":"Chico","year":"2023","journal-title":"Diabetes Technol Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1089\/dia.2022.0206","article-title":"Real-world evidence supporting tandem control-IQ hybrid closed-loop success in the medicare and medicaid type 1 and type 2 diabetes populations","volume":"24","author":"Forlenza","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.2337\/dc22-0329","article-title":"Hybrid closed-loop systems and glycemic outcomes in children and adults with type 1 diabetes: real-world evidence from a U.S.-based multicenter collaborative","volume":"45","author":"Noor","year":"2022","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.2337\/dc24-0916","article-title":"Sustained 3-year improvement of glucose control with hybrid closed loop in children with type 1 diabetes while going through puberty","volume":"47","author":"Bismuth","year":"2024","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.2337\/dc23-0504","article-title":"Automated insulin delivery systems in children and adolescents with type 1 diabetes: a systematic review and meta-analysis of outpatient randomized controlled trials","volume":"46","author":"Zeng","year":"2023","journal-title":"Diabetes Care"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1177\/19322968231161320","article-title":"Advanced hybrid closed loop in adult population with type 1 diabetes: a substudy from the ADAPT randomized controlled trial in users of real-time continuous glucose monitoring","volume":"18","author":"van den Heuvel","year":"2024","journal-title":"J Diabetes Sci Technol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2337\/dc23-0635","article-title":"Hybrid closed-loop therapy in adults with type 1 diabetes and above-target HbA1c: a real-world observational study","volume":"46","author":"Crabtree","year":"2023","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1056\/NEJMoa2303911","article-title":"Automated insulin delivery in women with pregnancy complicated by type 1 diabetes","volume":"389","author":"Lee","year":"2023","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.2337\/dci21-0043","article-title":"The management of type 1 diabetes in adults. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"44","author":"Holt","year":"2021","journal-title":"Diabetes Care"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/dme.15078","article-title":"UK\u2019s association of British clinical diabetologist\u2019s diabetes technology network (ABCD-DTN): best practice guide for hybrid closed-loop therapy","volume":"40","author":"Griffin","year":"2023","journal-title":"Diabet Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.2337\/dc24-S007","article-title":"7. Diabetes technology: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.802419","article-title":"A comparison of two hybrid closed-loop systems in Italian children and Adults With type 1 diabetes","volume":"12","author":"Bassi","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1099024","article-title":"One-year follow-up comparison of two hybrid closed-loop systems in Italian children and Adults with type 1 diabetes","volume":"14","author":"Bassi","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/19322968241230106","article-title":"Retrospective comparison of commercially Available Automated insulin delivery with open-source automated insulin delivery systems in type 1 diabetes","author":"Sch\u00fctz","year":"2024","journal-title":"J Diabetes Sci Technol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.endinu.2023.06.005","article-title":"Patient satisfaction in three advanced hybrid closed-loop systems at 6 months of treatment in adults with type 1 diabetes mellitus: a follow-up study","volume":"70","author":"Navas Moreno","year":"2023","journal-title":"Endocrinol Diabetes Nutr"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1111\/dom.14439","article-title":"A real-world study of user characteristics, safety and efficacy of open-source closed-loop systems and medtronic 670G","volume":"23","author":"Jeyaventhan","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1056\/NEJMoa1907863","article-title":"Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes","volume":"381","author":"Brown","year":"2019","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0140-6736(18)31947-0","article-title":"Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial","volume":"392","author":"Tauschmann","year":"2018","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S2213-8587(22)00212-1","article-title":"Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study","volume":"10","author":"Pharmd","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1089\/dia.2022.0558","article-title":"A meta-analysis of randomized trial outcomes for the t: slim X2 insulin pump with control-IQ technology in youth and adults from age 2 to 72","volume":"25","author":"Beck","year":"2023","journal-title":"Diabetes Technol Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/dmrr.3842","article-title":"Efficacy and safety of different hybrid closed loop systems for automated insulin delivery in people with type 1 diabetes: a systematic review and network meta-analysis","volume":"40","author":"Di Molfetta","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1089\/dia.2023.0433","article-title":"Celebrating the data from 100,000 real-world users of the MiniMedTM 780G system in Europe, Middle East, and Africa collected over 3 years: from data to clinical evidence","volume":"26","author":"Choudhary","year":"2024","journal-title":"Diabetes Technol Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/S2589-7500(19)30003-2","article-title":"Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial","volume":"1","author":"Benhamou","year":"2019","journal-title":"Lancet Digit Health"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf006","article-title":"Changes in 90-day time in range among youth with type 1 diabetes initiating different automated insulin delivery systems","volume":"15","author":"Gera","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1177\/1932296820986879","article-title":"The impact of a recently approved automated insulin delivery system on glycemic, sleep, and psychosocial outcomes in older adults with type 1 diabetes: a pilot study","volume":"16","author":"Bisio","year":"2022","journal-title":"J Diabetes Sci Technol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2337\/dc23-1355","article-title":"A multicenter prospective evaluation of the benefits of two advanced hybrid closed-loop systems in glucose control and patient-reported outcomes in a real-world setting","volume":"47","author":"Beato-V\u00edbora","year":"2023","journal-title":"Diabetes Care"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.2337\/dc23-0685","article-title":"Safety and efficacy of sustained automated insulin delivery compared with sensor and pump therapy in adults with type 1 diabetes at high risk for hypoglycemia: a randomized controlled trial","volume":"46","author":"Renard","year":"2023","journal-title":"Diabetes Care"},{"key":"B33","doi-asserted-by":"publisher","first-page":"110730","DOI":"10.1016\/j.diabres.2023.110730","article-title":"Switching from treatment with sensor augmented pump to hybrid closed loop system in type 1 diabetes: impact on glycemic control and neuropsychological tests in the real world","volume":"201","author":"Amig\u00f3","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"B34","doi-asserted-by":"publisher","first-page":"111114","DOI":"10.1016\/j.diabres.2024.111114","article-title":"Patient reported outcomes (PROs) and user experiences of young children with type 1 diabetes using t: slim X2 insulin pump with control-IQ technology","volume":"208","author":"Hood","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"B35","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.endinu.2023.06.005","article-title":"Satisfacci\u00f3n del paciente en tres sistemas avanzados de asa cerrada h\u00edbrida a los 6 meses de tratamiento en adultos con diabetes mellitus tipo 1: un estudio de seguimiento","volume":"70","author":"Navas Moreno","year":"2023","journal-title":"Endocrinol Diabetes Nutr"}],"container-title":["Frontiers in Digital Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2025.1596188\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:27:55Z","timestamp":1751347675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2025.1596188\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":35,"alternative-id":["10.3389\/fdgth.2025.1596188"],"URL":"https:\/\/doi.org\/10.3389\/fdgth.2025.1596188","relation":{},"ISSN":["2673-253X"],"issn-type":[{"value":"2673-253X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"article-number":"1596188"}}